AUPH Aurinia Pharmaceuticals Inc

-0.06  -1%
Previous Close 6.31
Open 6.27
Price To Book 5
Market Cap 556630063
Shares 89,060,810
Volume 172,782
Short Ratio
Av. Daily Volume 779,594

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released January 22, 2019. Primary endpoint not met, secondary met.
Voclosporin Ophthalmic Solution (VOS)
Dry eye syndrome
Phase 2 trial initiation announced June 2018. Interim data readouts are anticipated from mid-2019.
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Phase 3 data due 4Q 2019.
Voclosporin - AURORA
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2

Latest News

  1. Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
  2. Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
  3. Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
  4. Aurinia: 4Q Earnings Snapshot
  5. Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
  6. Aurinia Pharmaceuticals Inc. to Host Earnings Call
  7. Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
  8. Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
  9. Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019
  10. After Patent News, Aurinia Pharmaceuticals Still Has More to Prove
  11. Aurinia Closes At-The-Market Facility
  12. Big Pharma faces the Senate in drug price hearings
  13. Here's Why Aurinia Pharmaceuticals' Stock Jumped Today
  14. Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
  15. Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City
  16. Is Aurinia Pharmaceuticals a Buy?
  17. Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth
  18. Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial
  19. Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
  20. Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome